Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD200 (Jornay PM) in Children with ADHD
NCT02520388Phase 3Completed
- Sponsor
- Ironshore Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing HLD200 with Placebo (2 arms). Primary endpoint: Attention Deficit Hyperactivity Disorder Rating Scale IV Total Score at 3 weeks. Started Aug 2015; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02520388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520388.